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Background: Prostate-specific antigen (PSA)ebased screening for prostate cancer has been widely
performed, but its accuracy is unsatisfactory. To improve accuracy, building an effective statistical model
using machine learning methods (MLMs) is a promising approach.
Methods: Data on continuous changes in the PSA level over the past 2 years were accumulated from 512
patients who underwent prostate biopsy after PSA screening. The age of the patients, PSA level, prostate
volumes, and white blood cell count in urinalysis were used as input data for the MLMs. As MLMs, we
evaluated the efficacy of three different techniques: artificial neural networks (ANNs), random forest, and
support vector machine. Model performance was evaluated using area under the receiver operating
characteristic curve (AUC) and compared with the PSA level and the conventional PSAebased parame-
ters: PSA density and PSA velocity.
Results: When using two annual PSA testing, all receiver operating characteristic curves of the three
MLMs were above the curve for the PSA level, PSA density, and PSA velocity. The AUCs of ANNs, random
forest, and support vector machine were 0.69, 0.64, and 0.63, respectively. Those values were higher than
the AUCs of the PSA level, PSA density, and PSA velocity, 0.53, 0.41, and 0.55, respectively. The accuracies
of the MLMs (71.6% to 72.1%) were also superior to those of the PSA level (39.1%), PSA density (49.7%), and
PSA velocity (54.9%). Among the MLMs, ANNs showed the most favorable AUC. The MLMs showed higher
sensitivity and specificity than conventional PSAebased parameters. The model performance did not
improve when using three annual PSA testing.
Conclusion: The present retrospective study results indicate that machine learning techniques can
predict prostate cancer with significantly better AUCs than those of PSA density and PSA velocity.
© 2019 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate-specific antigen (PSA)ebased screening for prostate
cancer (PCA) has been widely performed in many countries. PSA is
produced by prostate epithelium; therefore, it is organ specific but
is not a PCA-specific marker. PSA can be elevated in patients with, Hitachi General Hospital, 2-
077, Japan.
Nitta).
te Society, Published by Elsevierbenign prostate hypertrophy, prostatitis, or other non-PCA condi-
tions. The low specificity of PSA can lead to unnecessary biopsy. The
sensitivity of PSA is also unsatisfactorydit is limited to around 50%
based on a widely used cutoff level of 4 ng/ml. To improve the
accuracy of screening systems, various approaches such as mea-
surements of free PSA, PSA density, PSA velocity, and introduction
of the age-specific PSA reference range have been proposed.1e3 The
results are promising; however, they do not show sufficiently
strong diagnostic accuracy on their own.Korea LLC. This is an open access article under the CC BY-NC-ND license (http://
S. Nitta et al. / Machine learning methods 115To overcome these obstacles, building an effective statistical
model using various predictive variables is a promising approach.
For this purpose, machine learning techniques have been used
extensively in the field of clinical medicine, especially when used
for the construction of predictionmodels. For prediction of PCA, the
machine learning technique most evaluated is artificial neural
network (ANN).4e12 ANNs show high area under the curve (AUC)
values compared with PSA alone (total PSA or other PSA-based
assessments), ranging from 0.67 to 0.87 depending on the
selected variables and the examined population. More recently, as
alternative machine learning methods (MLMs), support vector
machine (SVM) and random forest (RF) have been applied to PSA
screening.13,14 These new algorithms may help to improve diag-
nosis, but available information is limited.
Partly because of the low sensitivity and specificity of PSA, many
participants in PSA screening receive repeat PSA testing annually. In
general, participants with PSA above the cutoff levels are encour-
aged to undergo prostate biopsy. However, conservative attitudes
toward making the decision to receive an invasive procedure
sometimes cause participants to select repeat PSA testing rather
than promptly opt for prostate biopsy. In addition, several guide-
lines recommend annual PSA testing for menwith PSA below 4 ng/
ml. The Japanese Urological association (JUA) recommends annual
PSA testing formenwith PSA levels 1e4 ng/ml.15 The NCCN Prostate
Cancer Early Detection Panel recommends PSA testing at 1- to 2-
year interval for menwith PSA levels 1e3 ng/ml in the age group of
45e75 years.16 Such a frequent follow-up leads to multiple normal
or intermediately abnormal PSA test values. It can result not only in
psychological distress for participants but also in inefficient use of
medical resources.
Based on this background, we conducted the present retro-
spective study with the objective of building an effective statistical
model using two or three annual PSA testing before prostate biopsy.
For this purpose, we evaluated the efficacy of SVM and RF in
addition to the traditional machine learning technique, ANNs. To
our knowledge, there are no previous studies using annual PSA
testing to improve the accuracy of PSA screening.2. Patients and methods
2.1. Patients
The study was approved by the independent ethics committee
of Hitachi General Hospital. Between October 2002 and June 2016,Table 1
Distribution of diagnostic variables in 512 patients who underwent the first biopsy.
Characteristics Patients diagnosed with PCA
N ¼ 193
Age (year)
50e59 7
60-69 82
S70 104
Mean PSA level (ng/ml)a) 8.6
PSA (ng/ml)a)
<4 2
4 < PSA<10 149
10 & PSA<20 38
S20 4
Mean prostate volume (cc) 55.6
Mean PSA density (ng/ml/cc) 0.20
Mean PSA velocity (ng/ml/year) 0.96
PCA, prostate cancer; PSA, prostate-specific antigen.
a) Average of two serial PSA testing3,911 patients underwent prostate biopsy at Hitachi General Hos-
pital. We accumulated data on continuous changes in the PSA level
over the past 2 years from 3911 patients and excluded those pa-
tients who received drugs (e.g. dutasteride) that might affect the
PSA level. As a result, the overall study cohort (n ¼ 512) was
selected from 3911 patients. In addition, three continuous and
annually measured PSA values were available for 304 patients. All
patients underwent transurethral ultrasound sonography (TRUS)
before biopsy. The TRUS examinations were performed by well-
trained technicians. The PSA density was calculated by dividing
the PSA by the prostate volume (approximate values of ellipsoid:
anteroposterior diameter  lateral diameter  vertical
diameter  p/6). The PSA velocity was calculated as the rate of PSA
change using the first and last values only and the equation pn p1/
tn t1 [n¼ total number of PSA tests, p¼ PSA value, and t¼ time at
PSA test (yr)].
Of 512 patients,193 (37.7%) were diagnosedwith PCA on the first
prostate biopsy, which was performed using the 10-core transrectal
approach. Table 1 shows the baseline characteristics of the patients.
The mean PSA level and PSA distribution were not significantly
different between the patients diagnosed with PCA and those not
diagnosed with PCA. The mean prostate volume was significantly
higher in the former group compared with the latter group, but
there was no significant difference in PSA density and PSA velocity
between the two groups. Among 319 patients not diagnosed with
PCA at the first biopsy, 112 patients underwent a second or more
prostate biopsies. The rebiopsy was performed using the 12-core
transperitoneal approach. Of the 112 patients, 57 were eventually
diagnosed with PCA.2.2. Machine learning methods
Three types of supervised machine learning algorithms (ANNs,
SVM, and RF) were applied in this study. A set of input variables
comprising age of patients, PSA level (maximum, minimum, me-
dian, mean, and variance level), prostate volumes, white blood cell
(WBC) count in urinalysis, and result of biopsy was used to create
the PCA prediction model. Age of patients, PSA level, and prostate
volumes were entered as continuous variables, and the WBC count
in urinalysis was entered as seven categorical variables from below
1 WBC/high-power field to 50-99 WBC/high-power field. The re-
sults of biopsy were entered as binary: 1 (PCA) and 0 (non-PCA).
The machine learning models were fit using scikit-learn 0.18
modules of python throughout this study. The ANNmodels were fitPatients with negative biopsy P value
N ¼ 319
0.52
30
149
140
4.5 0.08
0.67
9
260
47
3
44.8 <0.05
0.19 0.87
0.71 0.08
Fig. 1. Receiver operating characteristic curve for prediction of prostate cancer diag-
nosis on the first therapy is shown.
ANNs, artificial neural networks; PSA, prostate-specific antigen; RF, random forest;
SVM, support vector machine.
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perceptron is a feedforward ANNmodel that maps sets of input data
onto sets of appropriate outputs. There can be one or more
nonlinear hidden layers between the input and the output. The
input neurons send information to the hidden layer, and the hidden
layer sends data to the output layer. Every neuron in the hidden
layer has weighted inputs, a nonlinear activation function (which
defines the output, given an input), and one output. There are two
main tuning parameters: the number of nodes in the hidden layer
and activation function. Training is the weight optimization process
in which the error of predictions is minimized and the network
reaches a specified level of accuracy. The SVM model is a machine
learning model that finds an optimal boundary between the
possible outputs. SVM identifies the optimal separating hyperplane
that maximizes the margin between the output and input. The SVM
models were fit using the SVC class of scikit-learn. There are three
main tuning parameters: penalty parameter C, kernel type, and
gamma. Parameter C handles the trade-off betweenmaximizing the
margin and minimizing the training error; increasing the value
improves the classification accuracy for the training data but could
lead to overfitting. Kernel type defines the type of nonlinear kernel
function (tanh, radial basis function (RBF), polynomial) used for the
separation. Gamma is used for kernel functions. Increasing the
gamma value improves the classification accuracy for the training
data, but this could lead to overfitting. The RF model is a machine
learning model built on decision trees. In the decision tree, each
node of the tree splits the data into two groups using a cutoff value
within one of the features. As the depth increases, the decision tree
tends to overfit the training data; the tree fits details of particular
data rather than the overall properties of the distributions. The RF
method is able to minimize the effect of the overfitting problem by
creating an ensemble of randomized decision trees, each of which
overfits the data and averages the results to find a better classifi-
cation. Increasing the number of trees improves the accuracy for the
training, but the cost in terms of computation time for learning is
increased.
For all the three models, the parameters of the estimator were
optimized by 10-fold cross-validated grid search over a parameter
grid. For each of the 10 “folds,” a model was trained using nine of
the folds as training data and the resulting model was validated on
the remaining part of the data. For each parameter set in the
parameter grid, 10-fold cross-validations were evaluated and the
best parameter set was selected.
2.3. Statistical analysis
Continuous variables were compared using the independent
sample Student t test. Model performancewas evaluated using area
under the receiver operating characteristic (ROC) curve (AUC),
which provides ameasure of the discriminatory performance of the
model17; sensitivity, which is the proportion of true positives that
are classified as such; specificity, which measures the proportion of
correctly identified true negatives; and accuracy, which is the
proportion of correct predictions.
3. Results
Fig. 1 shows the corresponding ROC curves for ANNs, SVM, and
RF using two annual PSA testing to predict pathological diagnosis of
the first biopsy in 512 patients. The results were compared with
those of the PSA level (cutoff of 4 ng/ml), PSA density (cutoff of
0.20 ng/ml/cc), and PSA velocity (cutoff of 0.75 ng/ml/year). As
shown in Fig. 1, all the ROC curves of the three MLMs were above
the curve for the PSA level, PSA density, and PSA velocity. In addi-
tion, we compared the ROC curves of those methods to predict theresult of the second or more biopsy in combinationwith the results
of the first biopsy. After subsequent biopsies, 250 of 512 patients
were finally diagnosed as having PCA. In this case, the ROC curves of
the threeMLMswere above the curve for the PSA level, PSA density,
and PSA velocity (Fig. 2).
Table 2 shows the AUC, sensitivity, specificity, and accuracy of
each prediction method for the results of the first biopsy. When
using AUC as a measure of predictive model performance, as shown
in Table 2, the AUC of ANNs was 0.69. It was superior to those of RF
and SVM (0.64 and 0.63, respectively). The AUCs of the PSA level,
PSA density, and PSAvelocity were 0.53, 0.41, and 0.55, respectively,
which were lower than those of the MLMs.
As show in Table 2, the accuracies of the three MLMs were also
superior to those of the PSA level, PSA density, and PSAvelocity. The
sensitivities of the MLMs were 56.4 to 66.7%, which were higher
than those of PSA density and PSA velocity. Furthermore, the
specificities of the MLMs tended to be higher than conventional
PSAerelated parameters.
We further analyzed the predictive performance of the three
MLMs using three annual PSA testing. As shown in Table 3, AUCs of
ANNs, RF, and SVM were 0.70, 0.68, and 0.71, respectively. Those
were slightly superior to AUCs using two annual PSA testing. In
addition, the accuracies, sensitivities, and specificities were higher
than those using two annual PSA testing.
4. Discussion
As machine learning techniques, ANNs were first introduced
into PCA diagnosis in 1994 by Snow et al. .4 The authors used age,
PSA level, digital rectal examination (DRE), and TRUS findings as
input data and reported the excellent AUC of 0.87. Since then, ANNs
have been widely used for this purpose. However, reported AUCs
ranged from 0.67 to 0.88 depending on the selected variables and
the examined population. According to reviews by Schroder and
Kattan,12 seven of the eight ANN studies used DRE findings as
variables. In six studies, percent free PSA was also introduced as a
variable. Here, we showed that machine learning techniques using
themore simple predictors as input data can efficiently predict PCA.
Our analyses have provided the following interesting findings.
In the present study, we used age, PSA level, prostate volume,
and WBC count in urinalysis as variables. The WBC count in uri-
nalysis was selected in attempting to exclude PSA elevation due to
prostatitis. We excluded DRE as a variable to avoid subjective
Table 2
Diagnostic performance of different prediction methods using two serial PSA testing and PSA-related parameter.
Outcome Artificial neural network Random forest Support vector machine PSA density PSA velocity PSA
AUC 0.69 0.64 0.63 0.41 0.55 0.53
Sensitivity (%) 56.4 66.7 59.0 37.2 47.1 99.0
Specificity (%) 76.6 56.2 68.7 57.3 60.8 2.8
Accuracy (%) 71.6 72.1 71.6 49.7 54.9 39.1
AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen.
Table 3
Diagnostic performance of different prediction methods using three serial PSA testing.
Outcome Artificial neural network Random forest Support vector machine
AUC 0.70 0.68 0.71
Sensitivity (%) 59.1 72.7 68.2
Specificity (%) 64.1 64.1 79.5
Accuracy (%) 72.4 65.8 74.1
AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen.
S. Nitta et al. / Machine learning methods 117factors. The three examined MLMs revealed both favorite AUCs of
0.63 to 0.69, which were better than that of the PSA level, PSA
density, and PSA velocity. We further analyzed the predictive per-
formance of the models by adding PSA density and PSA velocity as
variables, but this failed to further improve AUC (data not shown).
Therefore, it is possible that these models had already learned
factors associated with PSA density and PSA velocity.
As the JUA recommends annual PSA testing for men with PSA
levels 1e4 ng/ml,15 a number of Japanese PSA screening partici-
pants have prior two or more annual PSA data. Present prediction
models can help decision-making for prompt prostate biopsy or
further PSA follow-up. However, the model using three annual PSA
testing did not improve predictive performance, as shown in
Table 3. Therefore, it is possible that PSA levels over the past 2 years
were sufficient for this purpose. Although the JUA recommends
annual PSA testing, recently, individualized rescreening interval is
being proposed for men with PSA levels in the range 1e4 ng/ml.
Randazzo et al.18 conducted a population-based prospective
screening study and proposed a retest interval of every 3e4 years
for men with the baseline PSA of 1e2 ng/ml. The European Asso-
ciation of Urology recommendation is to postpone PSA follow-up
interval to 8 years for men with PSA of <2 ng/ml at the age of
60 years .19 In the future, if prediction models using PSA testing atFig. 2. Receiver operating characteristic curve for prediction of prostate cancer diag-
nosis on the first and second therapies is shown.
ANNs, artificial neural networks; PSA, prostate-specific antigen; RF, random forest;
SVM, support vector machine.optimal interval are developed, they could be a powerful tool for a
more individualized and scientific rescreening strategy.
Because there are no previous studies using annual PSA testing,
we compared three different models using the same variables and
population to identify the most suitable prediction model. In a
clinical situation, a relatively large number of variables compared
with the sample size have a tendency for overfitting bias in ma-
chine learnings. The RF model is known to be less prone to over-
fitting than the traditional ANNs or SVM.20 Therefore, RF may be a
candidate for a suitable model when using annual PSA testing.
However, in the present study, the AUC of RF was not superior to
those of ANNs, and our study did not have enough power to draw
conclusion on this point.
Although our study revealed important findings, there are
several limitations to our analysis. First, the sample size was rela-
tively small; therefore, further investigation is needed to establish a
prediction model. Second, many potential biases resulting from the
retrospective design of the analysis must be considered. Third, in-
formation about the decision-making process for prostate biopsy
selection was not fully available.
In conclusion, the present retrospective study showed that
machine learning techniques could predict a PCA diagnosis with
significantly better AUCs than those of PSA density and PSAvelocity.
It is possible that the three MLMs developed a tendency to detect
PCA from input data more effectively than human intelligence.
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